Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far.

Sky Zone CEO David Hoffman Talks Summer Economy
11:30

Claudia Sahm Talks US Jobs Report
08:09

Humilis's Brian Belski Talks Stock Market
12:01